Mylan NV (NASDAQ:MYL)

19.29
Delayed Data
As of Dec 06
 +0.39 / +2.06%
Today’s Change
16.63
Today|||52-Week Range
32.69
-29.60%
Year-to-Date
Better Buy: Pfizer vs. Bristol-Myers Squibb
7:00am / MotleyFool.com - Paid Partner Content
Why Sorrento Therapeutics Was Right to Reject Takeover Bids With A 245% Premium
Dec 05 / MotleyFool.com - Paid Partner Content
3 Dividend Stocks You Can Safely Hold for Decades
Dec 06 / MotleyFool.com - Paid Partner Content
Here's Why Revance Therapeutics Stock Is Falling Today
Dec 04 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close18.90
Today’s open19.02
Day’s range19.01 - 19.35
Volume5,057,626
Average volume (3 months)6,244,411
Market cap$10.0B
Data as of 4:00pm ET, 12/06/2019

Growth & Valuation

Earnings growth (last year)-46.92%
Earnings growth (this year)-6.00%
Earnings growth (next 5 years)+4.00%
Revenue growth (last year)-4.02%
P/E ratio214.3
Price/Sales1.24
Price/Book0.82

Competitors

 Today’s
change
Today’s
% change
BHCValeant Pharmaceutic...+0.16+0.55%
IONSIonis Pharmaceutical...+0.08+0.12%
JAZZJazz Pharmaceuticals...+1.36+0.92%
SRPTSarepta Therapeutics...-0.50-0.45%
Data as of 6:30pm ET, 12/06/2019

Financials

Next reporting dateFebruary 26, 2020
EPS forecast (this quarter)$1.28
Annual revenue (last year)$11.4B
Annual profit (last year)$352.5M
Net profit margin3.08%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Generic
No executives to display
Corporate headquarters
Hatfield, Hertfordshire

Forecasts